Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
This study explored a treatment combination (obinutuzumab, ibrutinib, and venetoclax) for a specific type of leukemia (chronic lymphocytic leukemia with del(17p) and/or TP53 mutation) in previously untreated patients. The treatment involved several cycles and aimed to achieve complete remission. The results showed that 58.5% of patients achieved complete remission, and after around 3 years, the…
